MedDataX Logo

Atrial Fibrillation Prior and Post Elective Cardioversion

NCT ID: NCT05926401

Last Updated: 2023-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardioversion from atrial fibrillation (AF) to sinus rhythm (SR) is performed primarily to improve patient symptoms. However, due to the intermittent nature of AF, patients may have converted to SR prior to elective cardioversion and the recurrence rate of AF after cardioversion can be high. The aims of this study are to assess the rate of spontaneously conversion to SR in patients with AF scheduled for elective cardioversion, as well as the rate of early recurrence of AF after elective cardioversion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Planned elective cardioversion for atrial fibrillation

ECG monitoring prior and after cardioversion

Intervention Type OTHER

Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECG monitoring prior and after cardioversion

Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Planned elective cardioversion of AF
* Informed written consent for participation

Exclusion Criteria

* Lack of ability to cooperate
* Pacemaker/CRT device
* No smart phone
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oslo University Hospital

OTHER

Sponsor Role collaborator

Sorlandet Hospital HF

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sigrun Halvorsen, PhD

Role: STUDY_CHAIR

Oslo university hospital /University of Oslo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sorlandet Hospital

Arendal, , Norway

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Norway

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jarle Jortveit, PhD

Role: CONTACT

Phone: +4799450714

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jarle Jortveit, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

543834

Identifier Type: -

Identifier Source: org_study_id